278 related articles for article (PubMed ID: 23001162)
1. Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.
Kaiser AD; Gadiot J; Guislain A; Blank CU
Cancer Immunol Immunother; 2013 Mar; 62(3):503-15. PubMed ID: 23001162
[TBL] [Abstract][Full Text] [Related]
2. Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.
Schuster K; Gadiot J; Andreesen R; Mackensen A; Gajewski TF; Blank C
Eur J Immunol; 2009 Nov; 39(11):2981-90. PubMed ID: 19658092
[TBL] [Abstract][Full Text] [Related]
3. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
4. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
6. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
[TBL] [Abstract][Full Text] [Related]
7. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
8. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.
Neeson P; Shin A; Tainton KM; Guru P; Prince HM; Harrison SJ; Peinert S; Smyth MJ; Trapani JA; Kershaw MH; Darcy PK; Ritchie DS
Gene Ther; 2010 Sep; 17(9):1105-16. PubMed ID: 20428216
[TBL] [Abstract][Full Text] [Related]
10. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
Kline J; Brown IE; Zha YY; Blank C; Strickler J; Wouters H; Zhang L; Gajewski TF
Clin Cancer Res; 2008 May; 14(10):3156-67. PubMed ID: 18483384
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction.
Nechushtan H; Pham D; Zhang Y; Morgensztern D; Yi KH; Shin SU; Federoff HJ; Bowers WJ; Tolba KA; Rosenblatt JD
Cancer Immunol Immunother; 2008 May; 57(5):663-75. PubMed ID: 17952436
[TBL] [Abstract][Full Text] [Related]
12. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells.
Zecher D; Li Q; Oberbarnscheidt MH; Demetris AJ; Shlomchik WD; Rothstein DM; Lakkis FG
J Immunol; 2010 Jun; 184(12):6649-57. PubMed ID: 20483732
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
14. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interleukin-7 induces proliferation of naive macaque CD4+ and CD8+ T cells in vivo.
Moniuszko M; Fry T; Tsai WP; Morre M; Assouline B; Cortez P; Lewis MG; Cairns S; Mackall C; Franchini G
J Virol; 2004 Sep; 78(18):9740-9. PubMed ID: 15331707
[TBL] [Abstract][Full Text] [Related]
16. Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential.
Berglund S; Gertow J; Magalhaes I; Mattsson J; Uhlin M
J Immunother; 2013 Oct; 36(8):432-41. PubMed ID: 23994891
[TBL] [Abstract][Full Text] [Related]
17. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells.
Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y
Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421
[TBL] [Abstract][Full Text] [Related]
18. IL-15-dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of IL-15.
Snell LM; Lin GH; Watts TH
J Immunol; 2012 Jun; 188(12):5915-23. PubMed ID: 22581858
[TBL] [Abstract][Full Text] [Related]
19. Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.
Perret R; Ronchese F
Eur J Immunol; 2008 Oct; 38(10):2886-95. PubMed ID: 18825745
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo.
Schluns KS; Kieper WC; Jameson SC; Lefrançois L
Nat Immunol; 2000 Nov; 1(5):426-32. PubMed ID: 11062503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
